What is the purpose of this study?This study is being done to find out how safe and how well the drug Tapinarof (VTAMA) works for stopping or treating palmoplantar keratoderma, which is a condition characterized by thickened skin on your palms and soles.  Tapinarof, used as a topical 1% cream, is a naturally occuring compound used for the treatment of psoriasis. While Tapinarof has been cleared by the FDA for treating psoriasis exclusively, its potential use for palmoplantar keratoderma still needs to be explored. Your participation in this study will contribute to providing valuable information that may lead to potential approval for palmoplantar keratoderma in the future. Who can take part?Anyone ages 18 and older who has palmoplantar keratoderma.Additional informationThe study is being conducted by Dr. David Rosmarin at the Indiana University School of Medicine, Department of Dermatology.. It is funded by Dermavant Sciences, who is also  the manufacturer of the drug.

What is the purpose of this study?This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. THIS STUDY IS ENROLLING BY INVITATION ONLY - Study staff will identify, screen and enroll subjects and perform visit procedures (i.e., vital signs, physical exams, pulmonary function tests, ECGs, blood draws and urine/sputum collection, administer questionnaires and investigational product, assess for adverse events and changes in medications, Chest CT [if applicable]). 

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.THIS STUDY IS ENROLLING BY INVITATION ONLY

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.  This study will evaluate the effects of the use of a program to reduce prescribing of a group of commonly prescribed medications called anticholingerics that may adversely effect cognitive functioning in older adults. THIS STUDY IS ENROLLING BY INVITATION ONLY - ResNet data managers will identify physicians from the medical records of Community Health Network, and these participating physicians' patients will be approached for recruitment.' They may be contacted by phone or during clinic visits upon referral from physician.  Physicians agreeing to participate in the study will be randomized to intervention or usual care in random blocks of two or four and stratified by clinic site. Physician randomization status will determine participants’ study groups. Physicians randomized to usual care will not have access to the intervention. Physicians are not the subjects of the study. The subjects are the patients of the physicians. Physicians will not be aware of how or when their patients are being recruited or for what studies they will be offered.

This sub-study consists of a single treatment group of men that require a PET scan to guide their radical prostatectomy, every subject will receive an MRI and the PSMA (prostate specific membrane antigen) PET scan prior to their surgery to determine if the PSMA PET scan is helpful in detecting prostate cancer at the edge of the prostate and guiding surgical treatment. The main outcome of this study is to review the sensitivity/specificity for extra-prostatic extension at the nerve bundles. A secondary goal for this cohort is to measure the proportion of patients whose treatment plan would be changed by PSMA-PET measured through changes in resection plans that affect one of 4 critical regions for quality of life.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632